Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

類似資料

• Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
  著者:: Pipe, Steven W., 等
  出版事項: (2020)
• Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
  著者:: Konkle, Barbara, 等
  出版事項: (2020)
• A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
  著者:: Young, Guy, 等
  出版事項: (2019)
• Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
  著者:: Callaghan, Michael U., 等
  出版事項: (2021)
• Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
  著者:: Shima, Midori, 等
  出版事項: (2017)